Nanjing IASO Biotechnology Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS5
PHASE 3 / 2-31
RECRUITING0
READOUTS ≤12 MONTHS2
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection NCT05091541 |
P1/2 | Not yet recruiting | B-cell Non-Hodgkin's Lymphoma | 125 | 2024-10-20 |
| Eque-cel CAR-T Therapy NCT07055724 |
P2 | Not yet recruiting | AL Amyloidosis | 17 | 2027-06 |
| FUMANBA-03 NCT06464991 |
P3 | Active, not recruiting | Multiple Myeloma | 260 | 2027-08 |
| FUMANBA-04 NCT07510100 |
P1/2 | Not yet recruiting | Relapsed/Refractory Multiple Myeloma | 17 | 2029-08-31 |
| Equecabtagene Autoleucel Injection (Eque-cel) NCT07752264 |
P1/2 | Not yet recruiting | Refractory Immune-mediated Necrotizing Myopathy | 27 | 2030-08-15 |